摘要
目的:评价我院干细胞移植患者术后早期抗感染药的应用情况。方法:调查我院2003～2008年30例干细胞移植患者从预处理至术后早期抗感染药的应用情况,包括病原学检查、抗感染药费用、应用例/次、应用时间、用药频度(DDDs)、药物利用指数(DUI)及抗感染药联用情况,分析其应用合理性。结果:干细胞移植患者术后26例出现感染,感染率达86.67%,病原学检查阳性11例;抗感染药总费用327598.23元;术后早期使用频率列前10位的抗感染药中,DUI<1的有7个,DUI>1的3个;联合用药中,二联38例/次(占73.08%),三联13例/次(占25.00%),四联1例/次(占1.92%)。结论:我院干细胞移植患者术后早期抗感染用药基本合理。
OBJECTIVE：To analyze the postoperative application of anti-infective agents in patients undergoing stem cell transplantation. METHODS：The application of anti-infective agents in 30 patients undergoing stem cell transplantation in the pretreatment period and after operation in our hospital from 2003 to 2008 were analyzed in respect of etiology inspection,the cost of anti-infective agents,utilization frequency（cases/times）,duration of medication,DDDs,DUI,drug combination and its rationality. RESULTS：The infection was found in 26 cases after operation,accounting for 86.67%. Pathogens were found out in 11 cases. The total cost of anti-infective agents was 327 598.23 yuan. The DUI of 7 kinds of top 10 anti-infective agents in terms of DDDs were less than 1 and that of other 3 were more than 1. In terms of drug combination,two-drug consisted of 73.08%（38 cases/times）, three-drug 25.00%（13 cases/times）and four-drug 1.92%（1 cases/times）. CONCLUSION：The postoperative application of anti-infective agents in patients undergoing stem cell transplantation in our hospital is rational on the whole.
出处
《中国药房》
CAS
CSCD
北大核心
2010年第22期2041-2044,共4页
China Pharmacy
关键词
干细胞移植
抗感染药
用药频度
分析
Stem cell transplantation
Anti-infective agents
DDDs
Analysis
